| Trial ID: | L3509 |
| Source ID: | NCT06291155
|
| Associated Drug: |
Sglt2 Inhibitor
|
| Title: |
Mechanism of SGLT2 Inhibition in the Kidney
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Diabetic Kidney Disease
|
| Interventions: |
DRUG: SGLT2 inhibitor
|
| Outcome Measures: |
Primary: Glomerular basement membrane (GBM) width and mesangial expansion, Measured by morphometric examination of kidney tissue, Baseline and 6 months | Secondary: Kidney Transcript Changes, Molecular changes measured by change in transcripts as assessed by single-cell RNA sequencing of kidney biopsy specimens, 6 month follow-up
|
| Sponsor/Collaborators: |
Sponsor: University of Michigan | Collaborators: University of Colorado, Denver|Renal Pre-Competitive Consortium (RPC3)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2024-01-01
|
| Completion Date: |
2028-06-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-03
|
| Locations: |
University of Michigan, Ann Arbor, Michigan, 48109, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06291155
|
